Human‑Safe Drug Restores Neuronal DNA Repair in Mouse Model of Alzheimer’s

Overview

• A paper published in July 2026 reports that KCL‑286, a selective retinoic acid receptor‑β (RARβ) agonist developed at King’s College London, reduced neuronal damage in an Alzheimer’s mouse model.
• Treated mice showed fewer neuronal DNA double‑strand breaks and higher neuronal BRCA1 protein levels, findings that point to enhanced DNA‑repair activity as the drug’s likely mechanism.
• KCL‑286 also normalized microglial and astrocyte morphology and lowered markers of neuroinflammation in the animals, linking DNA repair with reduced brain immune overactivation.
• KCL‑286 has completed a Phase I trial in healthy volunteers that reported no drug‑related adverse events and demonstrated blood‑brain‑barrier penetration, but no human efficacy data in Alzheimer’s exist yet.
• Authors call for funded early‑stage clinical trials, noting RARβ selectivity may avoid side effects of earlier retinoids and suggesting possible testing alongside approved amyloid‑lowering therapies if trials proceed.